: iStockAnalyst.com Symbols Feed

Bullish Stocks To Watch: BC, LUNA, DDRX, DRRX, JEF, DRAM, TSTR

Mon, 28 Sep 2009 13:23:04 GMT

Here is a list of 7 stocks which broke out during Friday's trade on big volume. I will be keeping my eye on all of these stocks this week, but chose only one to write a detailed option trade about this week. All of these stocks demonstrated tremendous strength during Friday's trade breaking out to the upside on huge volume.[More...]

FDA Calendar Updates: KG, PTIE, DRRX, ALTH, TRIB, CBST, DYAX

Tue, 07 Jul 2009 19:11:39 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 243 entries as of 7/7/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete respon (...)[More...]

Buy Durect Shares Up to $5

Thu, 12 Feb 2009 21:42:00 GMT

Durect Corp. (DRRX) utilizes 6 proprietary drug delivery technologies to develop pharmaceutical systems that enhance treatment capabilities in the areas of chronic pain, cardiovascular diseases and central nervous system disorders. The company received disappointing news when its lead pipeline candidate, Remoxy, failed to receive FDA approval in December 2008. While this news is a setback for the company, we believe that the product will ultimately receive approval and should see significant demand due to its ability to reduce the potential of drug abuse / misuse. Meanwhile, we remain optimistic on the remaining candidates in Durect's pipeline which consists of three candidates in phase II development. Moreover, we were pleased to hear about Durect's partnership deal with King ([More...]

Durect Headed in Right Direction - Analyst Blog

Tue, 04 Nov 2008 20:57:00 GMT

We are maintaining our Buy rating on Durect Corp. (DRRX). Durect has made significant progress with its pipeline and currently has three products in phase II development. These products are all addressing large market opportunities primarily in the pain management field. Importantly, the company filed its first NDA in June 2008. Another major positive for the company was the recent signing of a partnership agreement with Alpharma for the development and commercialization of Eladur. Going forward, potential milestones include the approval of Remoxy and the initiation of phase III trials for Posidur. Another major catalyst for the company would be the signing of a business deal for its pipeline candidates. Durect already has agreements in place for the development of Transdur-Sufentanil (with[More...]

Earnings Preview For Nov 3 - 7 - Earnings Preview

Sat, 01 Nov 2008 01:58:00 GMT

Companies that could issue positive surprises include Becton, Dickinson and Company (BDX), SucessFactors (SFSF) and Sunoco (SUN). Penn Virginia Corporation (PVA) could potentially disappoint investors. The Week's Events November has historically been one of the best months for the major markets, according to the[More...]

Analyst Comments: Autoliv, Fred, IPC Holdings, Durect, Williams Companies, Korea Electric Power, Anaren

Sun, 31 Aug 2008 18:44:00 GMT

Autoliv Inc. (ALV) is witnessing positive earnings growth by shifting production to low-cost regions and increased safety needs. Shares in global markets are increasing. However, difficult conditions in North American and West European automotive markets, as well as pricing pressure from original equipment manufacturers (OEM), are undermining Autoliv?s near-term prospects. Hence, we rate the stock a Hold with a target price of $34.50. Autoliv is set to grow globally by entering into partnerships and making acquisitions while introducing new safety products and streamlining its operations to cut costs. The company has a 40% global market share in airbags. The European market share is 65% and the North American market share for airbags is 38%. For seat belts, market share in North America rose to 28%, in Europe to 62%. Airbag and seatbelt market share in[More...]

Optimistic on Durect Pipeline

Thu, 26 Jun 2008 20:56:08 GMT

We are optimistic about Durect Corporation's (DRRX) pipeline, and are pleased to see that the company filed a New Drug Application (NDA) for its abuse-deterrent painkiller, Remoxy, on schedule. We also expect Durect to enter into a partnership deal for the Eladur pain patch shortly. This year should be catalyst-filled for the company, and we rate the shares a Buy. The...[More...]

Analyst Comments: Royal Dutch, Exxon, Durect, American Public Education, Interstate Hotels, Drugstore.com, Georgia Gulf

Fri, 09 May 2008 16:15:37 GMT

Royal Dutch Shell (RDS-A) reported sharply higher quarterly results, driven by strong upstream and gas & power segment earnings. The company's E&P arm experienced a 58% jump in profits, aided by high oil and gas prices. While we continue to believe that the group should benefit from the upstream momentum and restructuring initiatives in 2008, we see better investment opportunities in this space. The...[More...]

NASDAQ Technical Picture - Bearish Outside Day

Thu, 08 May 2008 05:05:24 GMT

The bears took over the ma[More...]

Analyst Comments: 3Com Corp, Jabil Circuit, Durect Corporation, Intevac, GlaxoSmithKline

Thu, 27 Mar 2008 23:03:11 GMT

With the acquisition by Bain Capital now off the table, 3Com Corporation (COMS) has begun trading on fundamentals of the business, which we believe are poor. Although a strong cash balance had provided support to COMS shares in the past, the acquisition of the remaining portion of its HC3 joint venture has eroded its cash position to $0.44 per share,...[More...]

DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)

Thu, 27 Aug 2009 11:56:00 GMT

DURECT Corporation today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY with King Pharmaceuticals, Inc. . This agreement stipulates the terms and conditions under which DURECT will supply to King, based on DURECT's manufacturing cost plus a specified percentage mark-up, two key excipients used in the manufacture of REMOXY.[More...]

DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma

Tue, 18 Aug 2009 11:56:00 GMT

DURECT Corporation today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, under which DURECT has granted to Orient Pharma development and commercialization rights in selected Asian and South Pacific countries to a drug candidate based on DURECT's ORADUR Technology and one specified active pharmaceutical ingredient for the treatment of attention deficit hyperactivity disorder . This drug candidate is intended to provide once-a-day dosing with added tamper-resistant characteristics to address common methods of abuse and misuse of these types of drugs. North American, European, Japanese and select other countries' rights to this drug candidate are retained by DURECT.[More...]

DURECT Corporation Announces Second Quarter 2009 Financial

Mon, 03 Aug 2009 20:01:00 GMT

Results[More...]

DURECT to Present at the BMO Capital Markets Healthcare Conference

Tue, 28 Jul 2009 20:51:00 GMT

CUPERTINO, Calif., July 28 /PRNewswire-FirstCall/ -- DURECT Corporation announced today that Matthew Hogan, Chief Financial Officer, will be presenting at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5 at 4:00 pm Eastern Time.
The conference is being held at the Millennium Broadway Hotel in New York City.
DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY , POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil.

[More...]

DURECT Corporation Invites You to Join Its Second Quarter 2009 Earnings Conference Call

Mon, 27 Jul 2009 20:26:00 GMT

In conjunction with DURECT Corporation's second quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Monday, August 3, 2009 at 4:30 pm Eastern Time .[More...]

REMOXY(R) NDA Update

Tue, 07 Jul 2009 11:00:00 GMT

DURECT Corporation today reported that King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. have announced that King met with the Food and Drug Administration on July 2, 2009 to discuss the Complete Response Letter regarding the New Drug Application for REMOXY. According to King Pharmaceuticals and Pain Therapeutics, the outcome of the meeting last week provided King with a clear path forward to resubmit the REMOXY NDA and to address all FDA comments in the Complete Response Letter.[More...]

DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy

Tue, 16 Jun 2009 20:01:00 GMT

DURECT Corporation announced today that Dr. Joseph Stauffer has joined DURECT as Chief Medical Officer and Executive Vice President, Corporate Strategy.[More...]

DURECT Corporation Announces First Quarter 2009 Financial Results

Wed, 06 May 2009 20:00:00 GMT

DURECT Corporation announced today financial results for the three months ended March 31, 2009. Total revenues were $6.2 million for the three months ended March 31, 2009, compared to $6.4 million for the same period in 2008. Net loss for the three months ended March 31, 2009 was $8.7 million, compared to a net loss of $7.8 million for the same period in 2008.[More...]

DURECT Corporation Invites You to Join its First Quarter 2009 Earnings Conference Call

Tue, 28 Apr 2009 20:25:00 GMT

In conjunction with DURECT Corporation's first quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, May 6, 2009 at 4:30 pm Eastern Time .[More...]

DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program

Mon, 16 Mar 2009 12:56:00 GMT

DURECT Corporation announced today positive results from a 74 patient Phase IIb clinical trial conducted by Endo Pharmaceuticals of TRANSDUR-Sufentanil, a proprietary seven day patch under development for the treatment of chronic pain. The development program for this drug candidate was reviewed with the U.S. Food and Drug Administration during a successful end-of-Phase II meeting with the FDA on February 19, 2009. As a result of that meeting, we believe we understand the anticipated regulatory pathway for the Phase III program and approval, which we expect will follow a 5052 pathway as discussed with FDA.[More...]